Total Return CAGR:17.53%(TTM)
Over the latest trailing 12-month period, total return cagr is +17.53%. The comparable SPY value is +22.28%. Year-to-date total return is +19.89%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Total Return CAGR averages 15.63% over 3 years and 11.90% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
DGX Total Return CAGR Chart
Quest Diagnostics Incorporated (DGX)
DGX Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
DGX Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 6927.08 | 8305.16 | +1378.08 | +19.89% | +19.89% |
| 2025 | 5910.04 | 6927.08 | +1017.03 | +17.21% | +17.21% |
| 2024 | 5287.38 | 5910.04 | +622.66 | +11.78% | +11.78% |
| 2023 | 5878.89 | 5287.38 | -591.51 | -10.06% | -10.06% |
| 2022 | 6375.66 | 5878.89 | -496.77 | -7.79% | -7.79% |
| 2021 | 4312.07 | 6375.66 | +2063.59 | +47.86% | +47.86% |
| 2020 | 3781.33 | 4312.07 | +530.74 | +14.04% | +14.04% |
| 2019 | 2883.26 | 3781.33 | +898.08 | +31.15% | +31.15% |
| 2018 | 3346.45 | 2883.26 | -463.19 | -13.84% | -13.84% |
| 2017 | 3065.68 | 3346.45 | +280.77 | +9.16% | +9.16% |
| 2016 | 2324.34 | 3065.68 | +741.34 | +31.89% | +31.89% |
| 2015 | 2145.17 | 2324.34 | +179.18 | +8.35% | +8.35% |
| 2014 | 1675.14 | 2145.17 | +470.02 | +28.06% | +28.06% |
| 2013 | 1786.72 | 1675.14 | -111.57 | -6.24% | -6.24% |
| 2012 | 1760.38 | 1786.72 | +26.33 | +1.50% | +1.50% |
| 2011 | 1624.31 | 1760.38 | +136.07 | +8.38% | +8.38% |
| 2010 | 1803.89 | 1624.31 | -179.58 | -9.96% | -9.96% |
| 2009 | 1538.83 | 1803.89 | +265.06 | +17.23% | +17.23% |
| 2008 | 1555.53 | 1538.83 | -16.71 | -1.07% | -1.07% |
| 2007 | 1546.68 | 1555.53 | +8.86 | +0.57% | +0.57% |
| 2006 | 1491.87 | 1546.68 | +54.81 | +3.67% | +3.67% |
| 2005 | 1375.20 | 1491.87 | +116.67 | +8.48% | +8.48% |
| 2004 | 1044.57 | 1375.20 | +330.63 | +31.65% | +31.65% |
| 2003 | 812.86 | 1044.57 | +231.71 | +28.51% | +28.51% |
| 2002 | 1024.57 | 812.86 | -211.71 | -20.66% | -20.66% |
| 2001 | 1014.29 | 1024.57 | +10.29 | +1.01% | +1.01% |
| 2000 | 218.29 | 1014.29 | +796.00 | +364.66% | +364.66% |
| 1999 | 127.14 | 218.29 | +91.14 | +71.69% | +71.69% |
| 1998 | 120.57 | 127.14 | +6.57 | +5.45% | +5.45% |
| 1997 | 108.00 | 120.57 | +12.57 | +11.64% | +11.64% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 8,305 | +5.9% | +18.1% |
| Q1 2026 | 7,843 | +12.0% | +19.6% |
| Q4 2025 | 7,005 | -6.7% | +18.0% |
| Q3 2025 | 7,505 | +6.7% | +24.1% |
| Q2 2025 | 7,035 | +7.2% | +32.1% |
| Q1 2025 | 6,559 | +10.5% | +27.8% |
| Q4 2024 | 5,936 | -1.8% | +13.2% |
| Q3 2024 | 6,047 | +13.6% | +27.6% |
| Q2 2024 | 5,323 | +3.7% | -0.8% |
| Q1 2024 | 5,132 | -2.2% | +1.2% |
| Q4 2023 | 5,244 | +10.7% | -11.0% |
| Q3 2023 | 4,739 | -11.7% | +1.3% |
| Q2 2023 | 5,367 | +5.9% | +5.7% |
| Q1 2023 | 5,070 | -13.9% | -4.9% |
| Q4 2022 | 5,892 | +25.9% | -4.7% |
| Q3 2022 | 4,679 | -7.8% | -16.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis